NetworkNewsBreaks – Sigyn Therapeutics Inc. (SIG
Post# of 124
(Total Views: 79)
Posted On: 05/07/2024 4:43:56 PM
NetworkNewsBreaks – Sigyn Therapeutics Inc. (SIGY) Announces Publication of Article on Emerging Candidate – Sigyn Therapy(TM)
Sigyn Therapeutics (OTCQB: SIGY), a development-stage medical technology company, today announced that it has published an article entitled: “Sigyn Therapy(TM), an Emerging Candidate to Address Endotoxemia, Sepsis and Drug-Resistant Viral & Bacterial Infections.” “When we designed Sigyn Therapy, we envisioned a medical device that could overcome the limitations of previous blood purification technologies to treat life-threatening conditions that are beyond the reach of drugs. Along with the efforts of our dedicated team, contributions from science advisors, collaborators and shareholders have helped to advance our vision toward reality,” said Jim Joyce, co-founder and CEO of Sigyn Therapeutics. “Consider that in the midst of the COVID-19 pandemic, we progressed Sigyn Therapy from concept through initial product development and then completed a series of five invitro study programs that validated the ability of Sigyn Therapy to extract twelve relevant therapeutic targets from human blood plasma. Subsequently, we completed first-in-mammal studies at the University of Michigan and then leveraged dialysis industry relationships to establish the treatment protocol, clinical site locations, and principal investigators for first-in-human studies of Sigyn Therapy.”
NOTE TO INVESTORS: The latest news and updates relating to SIGY are available in the company’s newsroom at https://nnw.fm/SIGY
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Sigyn Therapeutics (OTCQB: SIGY), a development-stage medical technology company, today announced that it has published an article entitled: “Sigyn Therapy(TM), an Emerging Candidate to Address Endotoxemia, Sepsis and Drug-Resistant Viral & Bacterial Infections.” “When we designed Sigyn Therapy, we envisioned a medical device that could overcome the limitations of previous blood purification technologies to treat life-threatening conditions that are beyond the reach of drugs. Along with the efforts of our dedicated team, contributions from science advisors, collaborators and shareholders have helped to advance our vision toward reality,” said Jim Joyce, co-founder and CEO of Sigyn Therapeutics. “Consider that in the midst of the COVID-19 pandemic, we progressed Sigyn Therapy from concept through initial product development and then completed a series of five invitro study programs that validated the ability of Sigyn Therapy to extract twelve relevant therapeutic targets from human blood plasma. Subsequently, we completed first-in-mammal studies at the University of Michigan and then leveraged dialysis industry relationships to establish the treatment protocol, clinical site locations, and principal investigators for first-in-human studies of Sigyn Therapy.”
NOTE TO INVESTORS: The latest news and updates relating to SIGY are available in the company’s newsroom at https://nnw.fm/SIGY
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)